Long to at least > 3.2, going parabolic assuming no more short term Series A unloading. Good fundamentals, analyst upgrades any week (as gauged from earnings call), and predicted 2+ sales by Q4 end. Loaded up and awaiting positive catalysts.
Komen:
More short positions during boring waiting period sowing doubt of commercialization, creating a better 2.36 buy in. Predicting at least one more sale by Q4 (could be international), then better guidance for Q1 18 as the 17-man sales team begin to make headway.